Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProvexis Regulatory News (PXS)

Share Price Information for Provexis (PXS)

Share Price is delayed by 15 minutes
Get Live Data
1.10    0.00 (0.00%)
Bid:
0.96
Ask:
1.10
Spread: 0.14 (14.583%)
Market Cap: £25.80m
PXS Live PriceLast checked at - London Stock Exchange

Intraday Provexis Share Chart

Product Launch

16 Dec 2005 07:00

Provexis PLC16 December 2005 PROVEXIS PLC ("Provexis" or the "Company") UK Launch of Sirco(TM) Provexis, the nutraceutical company that develops scientifically-provenfunctional and medical foods, is delighted to confirm the launch of itsSirco(TM) heart health juice drink in the UK in January 2006. The Company has so far secured an initial distribution base with two of the fivelargest supermarket retailers in the UK, which for reasons of commercialconfidentiality cannot be named at present. Both retailers will distributeSirco(TM) nationally. Within the larger of the two supermarket groups, Sirco(TM)will be initially available in premier stores which represent, by weighteddistribution, approximately 35 per cent. of their total UK distribution base.Within the second supermarket chain, Sirco(TM) will be initially available, byweighted distribution, across 70 per cent. of their total UK distribution base.Both retailers will stock Sirco(TM) in one litre packs of both flavour variants,Apple & Blueberry and Orange, and the drink will be located in the chilled fruitjuice section. The Company is in on-going discussions with a number of other retailers andhopes to make further distribution announcements in 2006. In addition to the onelitre packs, the Company is also developing a 250ml bottle of Sirco(TM) fordistribution to retailers in mid 2006. This bottle will have an extended shelflife and is intended to widen the distribution base to include independentchemists, convenience stores and food service industry channels such as health,education and travel outlets. Sirco(TM) is the first heart health product to contain the patentedFruitflow(TM) technology. Fruitflow(TM) was developed by Provexis in order tohelp regular "healthy" consumers reduce the risk of heart attack and stroke. Thenatural bioactive works by reducing blood platelet aggregation ("thinning theblood"), a significant contributing factor to a thrombosis (internal bloodclot). Sirco(TM) carries the health claim "Helps to Maintain a Healthy Heart andBenefits Circulation" and is approved by the leading heart health charity, HEARTUK. Commenting on the forthcoming launch Dr Stephen Franklin, CEO of Provexis, said: "This marks a significant milestone for Provexis and we are delighted that wehave secured distribution with two of the largest UK supermarkets. Bothretailers are ideal outlets in terms of the demographics and target market forthis product. We will be investing in media advertising as well as in-storeactivity to ensure we maximise this substantial opportunity. We look forward to growing the retailer base for Sirco(TM) throughout 2006,whilst in parallel securing licensing arrangements with major international foodpartners to integrate the FruitFlow(TM) technology into new food products inglobal markets." For further information please contact: Provexis plcDr Stephen Franklin 020 8392 6631 Bell Pottinger Corporate & FinancialAnn-Marie Wilkinson/Emma Kent 020 7861 3232 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
20th May 20267:00 amRNSHolding(s) in Company
16th Apr 202612:37 pmRNSHolding(s) in Company
31st Dec 20258:22 amRNSHalf-year Financial Report
31st Dec 20258:22 amRNSHalf-year Financial Report
21st Nov 20251:38 pmRNSResult of AGM
30th Oct 20257:30 amRNSRestoration - Provexis plc
30th Oct 20257:00 amRNSFinal Results
1st Oct 20257:30 amRNSSuspension - Provexis PLC
30th Sep 20258:40 amRNSDelay in publication of annual accounts
7th Jan 20251:14 pmRNSGrant of Options and Warrants
31st Dec 20241:00 pmRNSTotal Voting Rights
31st Dec 20249:59 amRNSHalf-year Report
18th Dec 20247:00 amRNSPurchase of Fruitflow® II SD & royalty payment
25th Oct 20243:47 pmRNSResult of AGM
30th Sep 20247:00 amRNSFinal Results
30th Apr 20245:00 pmRNSTotal Voting Rights
28th Mar 20247:00 amRNSIssue of Equity - purchase of Fruitflow® II SD
29th Dec 202312:48 pmRNSHalf-year Report
26th Oct 20231:51 pmRNSResult of AGM
29th Sep 20237:00 amRNSFinal Results
30th Aug 20237:04 amRNSBYHEALTH regulatory filing with Chinese SAMR
3rd Apr 20237:00 amRNSCapital structure and funding update
24th Jan 202311:03 amRNSGrant of Share Options
30th Dec 20228:53 amRNSHalf-year Report
27th Oct 20221:12 pmRNSResult of AGM
14th Oct 20227:00 amRNSDirectorate Change
30th Sep 20227:00 amRNSFinal Results
22nd Jun 20227:00 amRNSTwo new agreements with DSM & patent application
31st May 20225:00 pmRNSTotal Voting Rights
17th May 202212:39 pmRNSExercise of Options and Total Voting Rights
31st Dec 20217:00 amRNSHalf-year Report
26th Nov 20214:41 pmRNSSecond Price Monitoring Extn
26th Nov 20214:36 pmRNSPrice Monitoring Extension
4th Nov 20211:30 pmRNSResult of AGM
4th Nov 202111:07 amRNSBy-Health Fruitflow agreement and support in R&D
1st Oct 20216:04 pmRNSGrant of Share Options
30th Sep 20217:00 amRNSFinal Results
9th Sep 20214:41 pmRNSSecond Price Monitoring Extn
9th Sep 20214:35 pmRNSPrice Monitoring Extension
24th Aug 20214:35 pmRNSPrice Monitoring Extension
22nd Jul 20214:40 pmRNSSecond Price Monitoring Extn
22nd Jul 20214:35 pmRNSPrice Monitoring Extension
21st Jul 20214:41 pmRNSSecond Price Monitoring Extn
21st Jul 20214:36 pmRNSPrice Monitoring Extension
5th Jul 20214:35 pmRNSPrice Monitoring Extension
1st Jul 20214:40 pmRNSSecond Price Monitoring Extn
1st Jul 20214:35 pmRNSPrice Monitoring Extension
26th Feb 20215:00 pmRNSTotal Voting Rights
19th Feb 20217:30 amRNSDirector / PDMR notification
19th Feb 20217:00 amRNSPlacing of new ordinary shares to raise £50,000

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.